SAN FRANCISCO (AP) _ FibroGen Inc. (FGEN) on Monday reported a loss of $49.4 million in its third quarter.
The San Francisco-based company said it had a loss of 57 cents per share.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 59 cents per share.
The biotech drug developer posted revenue of $33.2 million in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $30.7 million.
FibroGen shares have dropped 24% since the beginning of the year. In the final minutes of trading on Monday, shares hit $35.39, a decline of 16% in the last 12 months.